Cargando…
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)
BACKGROUND: Elderly cancer patients form a heterogeneous population in which therapeutic decision-making is often difficult. The aim of this randomised phase II trial was to evaluate the feasibility and activity of weekly docetaxel/gemcitabine (DG) followed by erlotinib after progression (arm A) vs...
Autores principales: | LeCaer, H, Barlesi, F, Corre, R, Jullian, H, Bota, S, Falchero, L, Vergnenegre, A, Dujon, C, Delhoume, J Y, Chouaid, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208485/ https://www.ncbi.nlm.nih.gov/pubmed/21934690 http://dx.doi.org/10.1038/bjc.2011.331 |
Ejemplares similares
-
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
por: Christos, Chouaid, et al.
Publicado: (2012) -
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014) -
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015) -
Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020) -
Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
por: Vergnenegre, Alain, et al.
Publicado: (2019)